Drugs that contain Sacubitril; Valsartan
1. Drug name - ENTRESTO
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US8877938 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(4 years from now) | |
| CN101098689A | NOVARTIS PHARMS CORP | Medicinal Combination Product Of Angiotensin Receptor Antagonist And Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| CN102702119B | NOVARTIS PHARMS CORP | Pharmaceutical Composition Product With Angiotensin Receptor Antagonist And Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| CN101098689B | NOVARTIS PHARMS CORP | Pharmaceutical Composition Product With Angiotensin Receptor Antagonist And Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| CN102702119A | NOVARTIS PHARMS CORP | Pharmaceutical Composition Product With Angiotensin Receptor Antagonist And Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1948158B1 | NOVARTIS PHARMS CORP | Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| EP1948158A1 | NOVARTIS PHARMS CORP | Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And An Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| EP2340828B1 | NOVARTIS PHARMS CORP | Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And A Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| EP2340828A1 | NOVARTIS PHARMS CORP | Pharmaceutical Combinations Of An Angiotensin Receptor Antagonist And A Nep Inhibitor |
Nov, 2026
(4 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8404744 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2023
(3 months from now) | |
| US8796331 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2023
(3 months from now) | |
|
US8404744
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2023
(9 months from now) | |
|
US8796331
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2023
(9 months from now) | |
| US7468390 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Nov, 2023
(1 year, 1 month from now) | |
|
US7468390
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
May, 2024
(1 year, 7 months from now) | |
| US8101659 | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jan, 2025
(2 years from now) | |
|
US8101659
(Pediatric) | NOVARTIS PHARMS CORP | Methods of treatment and pharmaceutical composition |
Jul, 2025
(2 years from now) | |
| US9388134 | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2026
(4 years from now) | |
|
US9388134
(Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
May, 2027
(4 years from now) | |
|
US8877938
(Pediatric) | NOVARTIS PHARMS CORP | Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations |
Nov, 2027
(5 years from now) | |
| US9937143 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
| US9517226 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
| US11135192 | NOVARTIS PHARMS CORP | Inhibitors for treating diseases characterized by atrial enlargement or remodeling |
Aug, 2033
(10 years from now) | |
| US11058667 | NOVARTIS PHARMS CORP | Sacubitril-valsartan dosage regimen for treating heart failure |
May, 2036
(13 years from now) | |
Treatment: Treatment of heart failure; Treatment of heart failure with preserved ejection fraction; Treating chronic heart failure with reduced ejection fraction in patients not taking an ace inhibitor or an arb or previously taking low doses of these agents, by titrating up from half the usually recommended starting dose
Dosage: TABLET;ORAL
| Strength | Dosage | Availability |
|---|---|---|
| 24MG;26MG | TABLET;ORAL | Prescription |
| 49MG;51MG | TABLET;ORAL | Prescription |
| 97MG;103MG | TABLET;ORAL | Prescription |
availability in other generic markets.
Click on the highlighted region to filter.